Results filtered:Study status:
Closed for Enrollment
Closed for Enrollment
Addressing Diabetes Together: Implementation of a Regional Partnership for Population Health Management in Southeast Minnesota
Integration of Diabetes Prevention Program (DPP) and Diabetes Self Management Program (DSMP) into WellConnect.
Community Paramedic Hospitalization Reduction and Mitigation Program: Pragmatic Clinical Trial
Eau Claire, Wis.
The purpose of this study is to evaluate the effectiveness of the Care Anywhere with Community Paramedics (CACP) program in reducing hospitalizations among patients being cared for in the emergency department or hospital.
Community Paramedicine Program to Improve Diabetes Management Among Adults Experiencing Severe Hypoglycemia (D-REM Hypo)
The purpose of this study is assess the feasibility, effectiveness, and acceptability of Diabetes-REM (Rescue, Engagement, and Management), a comprehensive community paramedic (CP) program to improve diabetes self-management among adults in Southeast Minnesota (SEMN) treated for servere hypoglycemia by the Mayo Clinic Ambulance Services (MCAS).
Patient Preferences for Second-line Type 2 Diabetes Medication Treatment Outcomes
It is unknown how patient preferences and values impact the comparative effectiveness of second-line medications for Type 2 diabetes (T2D). The purpose of this study is to elicit patient preferences toward various treatment outcomes (e.g., hospitalization, kidney disease) using a participatory ranking exercise, use these rankings to generate individually weighted composite outcomes, and estimate patient-centered treatment effects of four different second-line T2D medications that reflect the patient's value for each outcome.
QBSafe: a randomized trial of a novel intervention to improve care for people living with type
2 diabetes (QBSafe)
The purpose of this study is to determine whether usual care with the QBSafe intervention (comprised of conversation cards and materials) compared with usual care alone improves patient reported outcomes (principally Illness Intrusiveness Rating Scale) and clinical outcomes (change in hemoglobin A1c) among patients with type 2 diabetes and hemoglobin A1c >8%.